BR112015009042A2 - populações de célula renal e usos das mesmas - Google Patents

populações de célula renal e usos das mesmas

Info

Publication number
BR112015009042A2
BR112015009042A2 BR112015009042A BR112015009042A BR112015009042A2 BR 112015009042 A2 BR112015009042 A2 BR 112015009042A2 BR 112015009042 A BR112015009042 A BR 112015009042A BR 112015009042 A BR112015009042 A BR 112015009042A BR 112015009042 A2 BR112015009042 A2 BR 112015009042A2
Authority
BR
Brazil
Prior art keywords
cell populations
renal cell
biomarkers
making
methods
Prior art date
Application number
BR112015009042A
Other languages
English (en)
Other versions
BR112015009042B1 (pt
BR112015009042A8 (pt
Inventor
Bruce Andrew
JUSTEWICZ Dominic
W Ludlow John
Basu Joydeep
Guthrie Kelly
W Kelley Russell
Burnette Teresa
Original Assignee
Regenmedtx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenmedtx Llc filed Critical Regenmedtx Llc
Publication of BR112015009042A2 publication Critical patent/BR112015009042A2/pt
Publication of BR112015009042A8 publication Critical patent/BR112015009042A8/pt
Publication of BR112015009042B1 publication Critical patent/BR112015009042B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)

Abstract

abstract the present invention concerns enriched heterogeneous mammalian renal cell populations characterized by biomarkers, and methods of making and using the same. tradução do resumo resumo "populações de célula renal e usos das mesmas". a presente invenção envolve populações de célula renal de mamífero heterogêneas enriquecidas caracterizadas por biomarcadores e métodos de fazer e usar as mesmas. 1/1
BR112015009042-7A 2012-10-24 2013-10-24 Método para identificar uma população de célula renal heterogênea adequada para implantação e/ou desencadeamento de uma resposta regenerativa BR112015009042B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261718150P 2012-10-24 2012-10-24
US61/718,150 2012-10-24
US201361876616P 2013-09-11 2013-09-11
US61/876,616 2013-09-11
PCT/US2013/066707 WO2014066699A1 (en) 2012-10-24 2013-10-24 Renal cell populations and uses thereof

Publications (3)

Publication Number Publication Date
BR112015009042A2 true BR112015009042A2 (pt) 2017-07-04
BR112015009042A8 BR112015009042A8 (pt) 2017-10-10
BR112015009042B1 BR112015009042B1 (pt) 2021-10-19

Family

ID=49517782

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112015009042-7A BR112015009042B1 (pt) 2012-10-24 2013-10-24 Método para identificar uma população de célula renal heterogênea adequada para implantação e/ou desencadeamento de uma resposta regenerativa
BR122020018576-7A BR122020018576B1 (pt) 2012-10-24 2013-10-24 Método de preparação de uma composição terapêutica adequada para gerar uma resposta regenerativa em um rim de um indivíduo, composição terapêutica e uso da mesma

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020018576-7A BR122020018576B1 (pt) 2012-10-24 2013-10-24 Método de preparação de uma composição terapêutica adequada para gerar uma resposta regenerativa em um rim de um indivíduo, composição terapêutica e uso da mesma

Country Status (18)

Country Link
US (4) US20150246073A1 (pt)
EP (3) EP3901251A1 (pt)
JP (2) JP6509119B2 (pt)
KR (4) KR102160725B1 (pt)
CN (3) CN104937095B (pt)
AU (3) AU2013334276B2 (pt)
BR (2) BR112015009042B1 (pt)
CA (1) CA2889270A1 (pt)
DK (2) DK2912165T3 (pt)
ES (2) ES2876177T3 (pt)
HK (1) HK1215448A1 (pt)
HU (2) HUE054882T2 (pt)
NZ (2) NZ707873A (pt)
PL (2) PL3567099T3 (pt)
PT (1) PT2912165T (pt)
RU (1) RU2702721C2 (pt)
SI (1) SI2912165T1 (pt)
WO (1) WO2014066699A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013334276B2 (en) 2012-10-24 2019-07-04 Prokidney Renal cell populations and uses thereof
BR112019001409B1 (pt) * 2016-07-29 2022-03-03 Deepak Jain Uso de uma composição compreendendo uma população de células renais selecionadas para o tratamento de doença renal crônica
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
KR20190137112A (ko) * 2017-03-31 2019-12-10 디팍 자인 주사가능 세포 및 스캐폴드 조성물
EP3641811A4 (en) * 2017-06-21 2021-03-31 Timothy A. Bertram IMMUNPRIVILEGATED BIOACTIVE KIDNEY CELLS FOR TREATMENT OF KIDNEY DISEASE
JP7061766B2 (ja) * 2017-09-20 2022-05-02 学校法人同志社 Ｄｊ－１タンパク質産生促進用組成物
CN109266616A (zh) * 2018-08-21 2019-01-25 山西省人民医院 一种稳定表达aqp2蛋白的人源化小鼠足细胞模型及其构建方法和应用
EP3843760A4 (en) * 2018-08-31 2022-11-09 Timothy Bertram COMPOSITIONS WITH CELL-DERIVED VESICLES AND THEIR USES
CA3137915A1 (en) * 2019-05-02 2020-11-05 Timothy Bertram Treatment of kidney disease in subjects with kidney and/or urinary tract anomalies
CA3164358A1 (en) * 2020-01-28 2021-08-05 Kidneycure Ltd Process for kidney cell manufacture and treatment

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
DK0814778T3 (da) 1995-03-10 2001-09-17 Roche Diagnostics Gmbh Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf
US6224893B1 (en) 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
WO1999022781A2 (en) 1997-10-31 1999-05-14 Children's Medical Center Corporation Bladder reconstruction
AU766959B2 (en) 1998-04-20 2003-10-30 Genzyme Corporation Drug delivery of proteins from polymeric blends
DE19933582A1 (de) 1999-07-17 2001-01-18 Gerhard Rosenberger Vorrichtung zum Aufnehmen von Werkstücken und/oder Werkzeugen
US6991652B2 (en) 2000-06-13 2006-01-31 Burg Karen J L Tissue engineering composite
US7197470B1 (en) 2000-10-11 2007-03-27 Buzzmetrics, Ltd. System and method for collection analysis of electronic discussion methods
BR0208603A (pt) 2001-04-03 2004-03-02 Merck Patent Gmbh Marcadores de tumor para carcinoma de células renais
CN1639185A (zh) * 2002-01-03 2005-07-13 斯克里普斯研究学院 癌相关表位
CA2479254A1 (en) 2002-03-22 2003-10-02 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for renal disease
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
US20040139072A1 (en) 2003-01-13 2004-07-15 Broder Andrei Z. System and method for locating similar records in a database
US20050241012A1 (en) * 2003-10-17 2005-10-27 Nigam Sanjay K Multigene profiling in the kidney to tailor drug therapy
US20050108384A1 (en) 2003-10-23 2005-05-19 Lambert John R. Analysis of message sequences
US7788087B2 (en) 2005-03-01 2010-08-31 Microsoft Corporation System for processing sentiment-bearing text
US20080161231A1 (en) * 2005-03-18 2008-07-03 Kintan Pty. Ltd. Methods and compositions for promoting organ development
US20090304639A1 (en) * 2005-04-28 2009-12-10 Takashi Yokoo Method for preparing an organ for transplantation
CA2871840A1 (en) 2006-02-10 2007-08-23 Tengion, Inc. Scaffolds for organ reconstruction and augmentation
JP2009528639A (ja) 2006-02-28 2009-08-06 バズロジック， インコーポレイテッド ソーシャルメディアにおける会話を分析するためのソーシャル分析システムおよび方法
PL2078073T3 (pl) * 2006-10-12 2013-12-31 Ethicon Inc Komórki pochodzące z nerki oraz sposoby ich zastosowania w leczeniu i regeneracji tkanki
US8048636B2 (en) * 2007-03-05 2011-11-01 Northshore University Healthsystem Methods of screening for modulators of h2-calponin activity
EP2162529B1 (en) 2007-06-08 2019-03-27 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
RU2373942C2 (ru) * 2007-12-26 2009-11-27 Федеральное государственное учреждение "Научный Центр акушерства, гинекологии и перинатологии Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения хронической и острой почечной недостаточности с помощью фетальных стволовых и прогениторных клеток
EP4219762A1 (en) 2008-02-01 2023-08-02 The General Hospital Corporation Use of microvesicles in diagnosis and prognosis of medical diseases and conditions
EP2186883A1 (en) * 2008-11-04 2010-05-19 Fresenius Medical Care An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
AU2009313554B2 (en) 2008-11-04 2015-08-27 Inregen Cell-scaffold constructs
NZ601862A (en) 2008-11-12 2014-07-25 Tengion Inc Isolated renal cells and uses thereof
US20110065136A1 (en) * 2009-08-07 2011-03-17 Rules-Based Medicine, Inc. Methods and Devices for Detecting Glomerulonephritis and Associated Disorders
CA2780320A1 (en) * 2009-11-12 2011-05-19 Tengion, Inc. Rational design of regenerative medicine products
SG183171A1 (en) 2010-02-04 2012-09-27 Agency Science Tech & Res Use of novel markers of pluripotent stem cells
JP2013525077A (ja) 2010-05-03 2013-06-20 テンジオン， インク． 平滑筋細胞構築物
JP5974215B2 (ja) 2010-05-12 2016-08-24 リージェンメド（ケイマン）エルティーディー． 生理活性腎臓細胞
WO2011156642A1 (en) 2010-06-11 2011-12-15 Tengion, Inc. Erythropoietin-expressing adipose cell populations
WO2012064369A1 (en) 2010-11-10 2012-05-18 Tengion, Inc. Injectable formulations for organ augmentation
BR112014007676A2 (pt) * 2011-09-30 2017-04-18 The Univ Of Miami células-tronco renais isoladas do rim
EP3425391A1 (en) 2011-11-04 2019-01-09 inRegen Drug screening and potency assays
AU2013334276B2 (en) 2012-10-24 2019-07-04 Prokidney Renal cell populations and uses thereof
WO2014066698A1 (en) 2012-10-24 2014-05-01 Metavana, Inc. Method and system for social media burst classifications
HRP20240170T1 (hr) 2013-05-08 2024-04-12 Prokidney Organoidi koji sadrže izolirane renalne stanice i njihove uporabe
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
EP3641811A4 (en) * 2017-06-21 2021-03-31 Timothy A. Bertram IMMUNPRIVILEGATED BIOACTIVE KIDNEY CELLS FOR TREATMENT OF KIDNEY DISEASE
AU2021377272A1 (en) * 2020-11-13 2023-06-22 Timothy A. Bertram Enriched bioactive renal cell populations, characteristics and uses thereof

Also Published As

Publication number Publication date
EP2912165B1 (en) 2019-06-19
ES2744979T3 (es) 2020-02-27
US10363274B2 (en) 2019-07-30
KR20220150419A (ko) 2022-11-10
WO2014066699A1 (en) 2014-05-01
EP3567099A1 (en) 2019-11-13
US20220347221A1 (en) 2022-11-03
KR102160725B1 (ko) 2020-09-29
CA2889270A1 (en) 2014-05-01
AU2019204178B2 (en) 2021-11-18
KR102215476B1 (ko) 2021-02-17
AU2013334276A1 (en) 2015-05-14
ES2876177T3 (es) 2021-11-12
KR20210018965A (ko) 2021-02-18
JP6509119B2 (ja) 2019-05-08
KR20200113287A (ko) 2020-10-06
JP6696023B2 (ja) 2020-05-20
PL3567099T3 (pl) 2021-11-29
BR112015009042B1 (pt) 2021-10-19
AU2022201010A1 (en) 2022-03-03
SI2912165T1 (sl) 2019-11-29
EP3901251A1 (en) 2021-10-27
DK3567099T3 (da) 2021-06-07
EP3567099B1 (en) 2021-04-21
HK1215448A1 (zh) 2016-08-26
PT2912165T (pt) 2019-09-26
AU2019204178A1 (en) 2019-07-04
PL2912165T3 (pl) 2020-01-31
NZ741724A (en) 2020-02-28
CN110184232A (zh) 2019-08-30
CN117660296A (zh) 2024-03-08
RU2015119514A (ru) 2016-12-20
US20200101112A1 (en) 2020-04-02
HUE046176T2 (hu) 2020-02-28
CN104937095B (zh) 2019-06-07
EP2912165A1 (en) 2015-09-02
US20150246073A1 (en) 2015-09-03
CN110184232B (zh) 2023-10-20
KR102460536B1 (ko) 2022-10-31
CN104937095A (zh) 2015-09-23
BR112015009042A8 (pt) 2017-10-10
ES2744979T8 (es) 2020-04-28
AU2013334276B2 (en) 2019-07-04
HUE054882T2 (hu) 2021-10-28
JP2016504017A (ja) 2016-02-12
US20170281684A1 (en) 2017-10-05
NZ707873A (en) 2019-01-25
BR122020018576B1 (pt) 2022-07-05
RU2702721C2 (ru) 2019-10-09
RU2019118791A (ru) 2019-07-11
JP2019141067A (ja) 2019-08-29
DK2912165T3 (da) 2019-09-16
KR20150085818A (ko) 2015-07-24
US11369639B2 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
BR112015009042A2 (pt) populações de célula renal e usos das mesmas
UY34697A (es) Métodos para preparar análogos de nucleótidos
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
UY34765A (es) Compuestos novedosos.
UY34817A (es) Tienopirimidinas
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY33978A (es) Piridinonas bicíclicas nuevas.
UY34503A (es) ?sal de bromhidrato de pridopidina?
EA201390613A1 (ru) Обогащенный дейтерием расагилин
MX359769B (es) Metodos para descelularizar huesos.
ECSP13013036A (es) Alfa glucosidasa ácida modificada con procesamiento acelerado
UY4244Q (es) Diseño marinero de botella
UY34167A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
UY34767A (es) Inhibidores cíclicos del enlace éter de dgat1
UY34097A (es) Alineación de anticoagulante de cebado para extracción de sangre.
UY4213Q (es) Centro de distribución de energía
EA201300513A1 (ru) Волокна для контролируемого разложения
BR112015008824A2 (pt) linhagens melhoradas de microalgas e processo das mesmas
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
UY34553A (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
UY34677A (es) Imidazopiridazinas sustituidas
UY34312A (es) Compuesto de benzotiazolona
UY34408A (es) Nuevos moduladores de trpv3

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INREGEN (KY)

B25D Requested change of name of applicant approved

Owner name: INREGEN (KY)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/10/2013, OBSERVADAS AS CONDICOES LEGAIS.